Imlunestrant vs Tamoxifen (Soltamox)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Imlunestrant · Inluriyo

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04975308 · Phase 3 · active, not recruiting

EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.

Next expected readout: October 2028 · NCT07905001 (registry estimate)

Reported efficacy

Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)

Result source: NCT04975308

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointImlunestrantTamoxifen (Soltamox)
PFS, median5.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results
OS, median—Trial running · NCT0497530847.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result
ORR10.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
30%bn 47NCT02668666
Clinical benefit rate46.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
64%bn 47NCT02668666

PFS, median

Imlunestrant
5.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results
Tamoxifen (Soltamox)
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results

OS, median

Imlunestrant
—Trial running · NCT04975308
Tamoxifen (Soltamox)
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result

ORR

Imlunestrant
10.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
Tamoxifen (Soltamox)
30%bn 47NCT02668666

Clinical benefit rate

Imlunestrant
46.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
Tamoxifen (Soltamox)
64%bn 47NCT02668666
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Imlunestrant: 7 of 7 rows · Tamoxifen (Soltamox): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricImlunestrantTamoxifen (Soltamox)
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
44.1% (n=213)a,b,c,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
62.9% (n=213)
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
64% (n=47)b,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
9.4% (n=213)a,b,c,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
21.1% (n=213)
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30% (n=47)b,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
5.49 monthsa,b,c,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more doses
9.23 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.36 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.52 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.13 monthsb,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
2 other source trials
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
Dropout rate
25.7%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
45.1%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%e
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT01027416 · Phase na · registry result, not featured evidence
Discontinued due to AEs
3%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5.6%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—e
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—
NCT01027416 · Phase na · registry result, not featured evidence
Serious AEs
14.1%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.2%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
28.7%e
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01027416 · Phase na · registry result, not featured evidence
Most frequent reported AEs
diarrhoea 21.7%
nausea 18%
arthralgia 15.3%
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 86.5%
nausea 50%
anaemia 43.8%
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
e
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
arthralgia 33.3%
back pain 33.3%
headache 33.3%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
headache 32.1% (placebo 0%)
night sweats 32.1% (placebo 0%)
irritability 28.6% (placebo 0%)
NCT01027416 · Phase na · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Imlunestrant

ORR 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.07 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Tamoxifen (Soltamox)

PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Disease Free Survival 352 vs 388 Tamoxifen Followed by Exemestane count @ 143wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
show 1 more result
712 vs 714 Tamoxifen Followed by Exemestane count @ 260wk
NCT00036270 · Phase 3 · registry result, not featured evidence
Overall Survival 485 vs 476 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
Relapse Free Survival 499 vs 521 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
ORR 5.9% (n=17) @ 4wk
event count · % of participants
No placebo or comparator arm
NCT00118157 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 participants as posted
show 1 more result
18.6% (n=43) @ 24wk*
NCT00365599 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 participants as posted
Overall 100% (n=13)
responder rate · % of participants
No placebo or comparator arm
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 13 participants as posted
Breast Conserving Surgery 0% (n=15)
event count · % of participants
No placebo or comparator arm
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 0 participants as posted
Time to Progression 10.3 months
time to event · months
No placebo or comparator arm
NCT00365599 · Phase 2 · registry result, not featured evidence · combination

+ 3 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Imlunestrant · Inluriyo

Marketed by Eli Lilly

Approved in Breast Cancersmall molecule
Partial signal

NCT04975308 · Phase 3 · active, not recruiting

EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.

Next expected readout: October 2027 · NCT05514054 (registry estimate)

Reported efficacy

Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)

Result source: NCT04975308

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

Reported efficacy

Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)

Result source: NCT00066690

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Imlunestrant: 8 of 8 rows · Tamoxifen (Soltamox): 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricImlunestrantTamoxifen (Soltamox)
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
44.1% (n=213)a,b,c,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
62.9% (n=213)
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
64% (n=47)b,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
9.4% (n=213)a,b,c,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
21.1% (n=213)
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30% (n=47)b,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
PFS
time to event · months
5.55 vs 5.52 Investigator's Choice of Endocrine Therapy monthsa,e,f,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more doses
5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.2 vs 15.6 Endocrine Therapy monthse,f,d
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
5.49 monthsa,b,c,d
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more doses
9.23 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.36 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.52 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.13 monthsb,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
1 other source trial
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
Dropout rate
25.7%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
45.1%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6%E+OFSg
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
26.7%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
10%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
9.1%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
3.2%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
20%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
0%
NCT01614210 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
17.6%
NCT00499083 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5.6%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
13.2%E+OFSg
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
6.8%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
—
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
—TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
—TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
—Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
—
NCT01614210 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT00499083 · Phase 2 · registry result, not featured evidence
Serious AEs
14.1%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.2%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
37.5%E+OFSg
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
37.2%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
28.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
20.7%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
22.9%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
0%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
0%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
1.9%
NCT01614210 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
diarrhoea 21.7%
nausea 18%
arthralgia 15.3%
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 86.5%
nausea 50%
anaemia 43.8%
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
g
hot flashes/flushes 81.9%
pain - joint 77.7%
fatigue (asthenia, lethargy, malaise) 59%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
hot flashes/flushes 80%
pain - joint 69.5%
sweating (diaphoresis) 61.7%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
other/minor (not categorized) 24%
bone pain 20.9%
fatigue 15.6%
NCT00295646 · Phase 3 · registry result, not featured evidence
bone pain 29.3%
other/minor (not categorized) 24.9%
fatigue 18.2%
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
hot flashes 36.5%
nausea 21.2%
fatigue 9.6%
NCT01614210 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
bone pain 33.3%
hypokalemia 33.3%
mucositis oral 33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation context differs: eligible sex differs (FEMALE versus ALL).
  6. fTreatment context differs: combination versus monotherapy.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Imlunestrant

ORR 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.07 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Tamoxifen (Soltamox)

Disease-free Survival 86.6% (n=1015) vs 84.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
89% (n=1014) vs 84.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Breast Cancer-free Interval 88.4% (n=1015) vs 86.4% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
90.9% (n=1014) vs 86.4% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Distant Recurrence-free Interval 91.3% (n=1015) vs 90.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
93% (n=1014) vs 90.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 93.3% (n=1015) vs 91.5% (n=1018) Tamoxifen @ 416wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
92.1% (n=1014) vs 91.5% (n=1018) Tamoxifen @ 416wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Disease-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Recurrence-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Overall 74.2% (n=31)
responder rate · % of participants
No placebo or comparator arm
NCT01831076 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
show 2 more results
0% (n=5)*
NCT01831076 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
100% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 13 participants as posted
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 2 more results
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
14.3% (n=14)*
NCT00499083 · Phase 2 · registry result, not featured evidence · converted to % from 2 participants as posted

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imlunestrant's landscape · Tamoxifen (Soltamox)'s landscape